Birte F.
- Country
- Germany
- Department
- Klinik für Hämatologie, Onkologie und klin. Immunologie
Research Overview
- Phase III Randomized Trial of High-Dose Chemotherapy with Autologous Stem Cell Transplantation versus R-MP in Elderly Patients with Primary CNS Lymphoma
- Evaluation of Axicabtagene Ciloleucel CAR T-Cell Therapy in Relapsed or Refractory Primary Mediastinal B-Cell Lymphoma Patients
- Phase 3 Multicenter Randomized Trial of Venetoclax, Obinutuzumab, and Pirtobrutinib in Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Data & Insights
Has run more than one trial at 40 of 184 partner sites.
Specializations
Lymphoma Research
The investigator specializes in treating aggressive B-cell lymphomas with a particular focus on diffuse large B-cell lymphoma (DLBCL). Their research explores innovative therapeutic approaches for patients with challenging blood cancers.
- Advanced B-cell Lymphomas
- Treatment-Resistant Disease
- Novel Therapeutic Combinations
Additional expertise includes management of high-grade B-cell lymphoma and follicular lymphoma grade 3B.
Immunotherapy Applications
The investigator focuses on developing targeted immunotherapy strategies using antibody-drug conjugates and bispecific antibodies for hematologic malignancies.
- Targeted Therapy Development
- Immune System Modulation
- Combination Treatment Strategies
Their work emphasizes optimizing therapeutic responses in aggressive lymphomas through innovative treatment combinations.
Treatment Response Assessment
The investigator specializes in evaluating treatment efficacy and response assessment in lymphoid malignancies, with particular attention to remission outcomes.
- Response Rate Evaluation
- Remission Assessment
- Long-term Outcome Analysis
Their research encompasses comprehensive monitoring of treatment responses in refractory blood cancers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.